Skip to content

Tag Archives: Anthrax vaccines

  1. Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule June 7, 2011

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Food and Drug Administration, Fuad El-Hibri.

    No comments
  2. Emergent BioSolutions Reports Financial Results for Full Year 2010 April 13, 2011

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Financial Results, Fuad El-Hibri, Trubion Pharmaceuticals.

    No comments
  3. Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine January 4, 2011

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri.

    No comments
  4. Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010 October 23, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, NYSE, Vaccine.

    No comments
  5. Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine September 20, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States, United States Department of Health and Human Services, Vaccine.

    No comments
  6. Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine September 10, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Vaccine.

    No comments
  7. Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars August 30, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Fuad Elhibri, Scholars Program.

    No comments
  8. Emergent Revises Upward 2010 Financial Forecast August 3, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Maryland, United States, Vaccine.

    No comments
  9. Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax July 15, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States, United States Department of Health and Human Services, Vaccine.

    No comments
  10. Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians July 13, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Food and Drug Administration, Fuad El-Hibri, United States Department of Defense, United States Department of Health and Human Services.

    No comments
  11. Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments July 7, 2010

    Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States, Washington.

    No comments
  12. Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares August 14, 2009

    Posted in Chief executive officer, El-Hibri Fuad, Emergent, Emergent BioSolutions, Emergent BioSystems, Fuad El-Hibri, Shareholders.

    No comments
  13. Emergent BioSolutions flaunts $75m anthrax vaccine production facility July 23, 2009

    Posted in Uncategorized.

    No comments
    14. DeliciousDiggFacebook
    RSS FeedStumbleUponTwitter